Yeah and if you watched their last meeting they are betting
Yeah and if you watched their last meeting they are betting the whole farm on Dr Patentson and first revenue on a EUA for Long Haulers with revenue expected in July of 2022.
There is two things wrong with this prediction or future direction…
1) There will be no unmet medical need for Long Haulers so a EUA will not apply and we will have to seek a full BLA. The time needed for a BLA if everything was quick would be over a year. Not 8-9 months.
2) What does this mean about the coveted Brazil trials. Are they aware we have trials open and enrolling in Brazil? Yes they are but somehow they said that they don’t feel Brazil will make us any money and we will sell below cost and lose money. They said this in their meeting. It blew me away. They also said that it wasn’t worth even doing the trials because Brazil only represent 10% of the drug sales world wide. What a stupid comment. Let’s do some math.
Say we sold all 700,000 doses we promised Biomm. Say we sold them for half the USA price of $1500 or $750/2 because of the split with Biomm. This equals $375 dollars each. The cost of our last small batch of Leronlimab cost was $75/dose. $375-$75 cost = $300 a dose. Then multiply that by 700,000 doses x $300/dose = $210,000,000.
Do we stop this trial? Leave 210 million dollars on the table and walk away? Is this what they will do to us? Closetinvestor always said that they would only trial one indication at a time. Stop all trials and focus on the HIV BLA. Now they changed priorities and changed to Long Haulers for their first revenue.
What this sounds like to me is to purposely bankrupt our company if they were to take control. This group doesn’t know how to initiate priorities and prioritize what we have going on. Why would we cancel all trials to focus on one trial when our first approval could pay for everything. This groups seems lost and priorities are not aligned with what is currently happening. They don’t have enough sense to complete the trials we have started. This is amazing how stupid they look.
17
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Greenlight Networks Expands Fiber Internet Services Greenlight Networks, a prominent fiber-to-the-home internet provider, is set to expand its fiber services into a new area with a significant investment of $100 million. This expansion aims to enhance high-speed internet access for residents and small businesses, ushering in new opportunities for economic growth and...
Continue Reading
Understanding Meta Platforms in the Market In the rapidly evolving business environment, it’s crucial for investors to closely examine firms prior to making investment choices. This article will provide a detailed analysis of Meta Platforms (NASDAQ: META) within the context of its main rivals in the Interactive Media & Services sector. By reviewing essential financial...
Continue Reading
Exploring Preliminary Data on Early Redemptions In light of recent financial insights, Jyske Realkredit has released preliminary data regarding early redemptions, specifically focusing on prepayments related to bonds. This intriguing announcement is intended for stakeholders and interested parties looking to understand the dynamics of the bond market. Understanding Early...
Continue Reading
Eltek Ltd. Announces Strong Performance for Q3 2024 Eltek Ltd. (NASDAQ: ELTK), a world-leading manufacturer of advanced printed circuit board solutions, has recently reported remarkable financial results for its third quarter, demonstrating a meaningful surge in revenues and profits. The company’s commitment to innovative practices in the PCB sector is reflected in its...
Continue Reading
Excitement Grows for Palantir Technologies' AI Conference As Palantir Technologies prepares for its upcoming conference focused on artificial intelligence, industry experts are eagerly anticipating the insights that could come from this significant event. A key topic of discussion is the recent extension of Palantir's partnership with a major energy player. Strategic...
Continue Reading